Core Insights - Carillon Tower Advisers reported that small-cap stocks had marginal gains in Q4 2025, with the Russell 2000 Growth Index returning 13.01% and the Russell 2000 Value Index gaining 12.58% [1] - The firm anticipates a favorable year ahead for equity markets, highlighting potential opportunities in sectors such as Cyclicals, Healthcare, Information Technology, Financials, and Consumer spending as they head into 2026 [1] Company Analysis: Hims & Hers Health, Inc. (NYSE:HIMS) - Hims & Hers Health, Inc. is a leading telehealth platform offering a variety of health and wellness products and services, with a market capitalization of $3.704 billion [2] - The stock closed at $16.27 per share on February 17, 2026, with a one-month return of -43.68% and a 12-month decline of 76.33% [2] - The company has faced challenges due to regulatory changes and competition from major pharmaceutical companies, despite initial growth from its injectable GLP-1 weight loss drugs launched in May 2024 [3] - Hims & Hers is diversifying its offerings to include hormone replacement therapy and peptides for health and aging, positioning itself for long-term growth despite cautious near-term investor sentiment [3] Hedge Fund Interest - Hims & Hers Health, Inc. was held by 35 hedge fund portfolios at the end of Q3 2025, an increase from 34 in the previous quarter [4] - While the company shows potential as an investment, certain AI stocks are considered to offer greater upside potential with less downside risk [4]

Core Viewpoint - BofA Securities has lowered its price target for GoodRx Holdings to $2.60 from $3.00 while maintaining an Underperform rating due to ongoing uncertainty regarding the company's near-term growth outlook [1] Group 1: Market Conditions - Changes in the pharmacy ecosystem are expected to create additional headwinds for GoodRx through 2026, with retail pharmacy chains like CVS, Rite Aid, and Walgreens closing locations [2] - Reimbursement changes in the pharmacy market are anticipated to negatively impact GoodRx's core prescription transaction business in 2025 [2] - Recent shifts in pharmacy benefit manager contracts with plan sponsors may accelerate net pricing at the pharmacy counter, adding further uncertainty to GoodRx's primary revenue stream [2] Group 2: Company Developments - GoodRx has made progress in diversifying its revenue base over the past year, including launching new subscription offerings for erectile dysfunction, hair loss, and weight loss, as well as expanding partnerships with pharmaceutical manufacturers [3] - Despite these efforts, the majority of GoodRx's business remains tied to pharmacy benefit managers (PBMs), indicating a need for the company to strengthen its industry positioning to stabilize growth in 2026 and beyond [3] Group 3: Valuation and Rating - BofA reiterated its Underperform rating and reduced its price objective to $2.60, reflecting a valuation of 4.0x calendar-year 2026 EBITDA, down from 4.5x previously, aligning with lower peer multiples [4]

Core Insights - Hims & Hers has experienced significant growth in the telehealth market, with a stock increase of 449% since going public and 158% in the past year [1][2] - The company utilizes a subscription model that bypasses traditional insurance, allowing for direct delivery of medications to customers' homes [2][4] - Hims & Hers reported trailing-12-month revenue of $1.78 billion and aims to reach $2.3 billion by 2025 and $6.5 billion by 2030 [4][11][13] Business Model and Market Position - The subscription model has enabled Hims & Hers to dominate the telehealth prescription market, focusing on areas such as sexual health, hair loss, and mental health [2][4] - The company is expanding its offerings by partnering with Novo Nordisk to include the weight loss drug Wegovy in its marketplace [4][5] - Hims & Hers currently has 2.4 million active customers, with management identifying a potential market of over 100 million people [5] International Expansion - Hims & Hers is pursuing international growth through the proposed acquisition of competitor Zava, which serves 1.3 million active customers in Western Europe [7][8] - The acquisition is expected to enhance Hims & Hers' marketing capabilities and scale, facilitating entry into new markets [8][9] Financial Performance and Projections - The company reported a year-over-year sales growth of 111% last quarter, with projections to reach $2.3 billion in revenue by 2025 [11] - Hims & Hers aims for a profit margin of 20% by 2030, which could result in approximately $1.3 billion in annual earnings [13] - The current market capitalization is $12.3 billion, leading to a high price-to-earnings (P/E) ratio of 79, but potential for valuation adjustment as growth continues [12][13]